Featured StoryEditor's Pick
Latest Articles
GLP-1 Drugs Keep Earning New Uses — A Look at the Expanding Evidence
The drugs known as GLP-1 medicines — semaglutide, tirzepatide, and others — were developed for blood sugar control and became famous for weight loss. But over the past two years, they have steadily collected FDA approvals for conditions that have nothing directly to do with either: sleep apnea, chronic kidney disease, cardiovascular risk, and liver disease. Here's what the evidence shows, and the open questions that remain.
A Drug Class That Keeps Widening
GLP-1 receptor agonists — the class that includes semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), among others — have one of the more unusual trajectories in modern medicine. They were developed to lower blood sugar in type 2 diabetes. They became a cultural phenomenon for weight loss. And over the past two years, they have steadily accumulated regulatory approvals and trial evidence for conditions that, on the surface, seem unrelated to either: obstructive sleep apnea, chronic kidney disease, cardiovascular risk reduction, and metabolic liver disease.
This is worth understanding, because "a weight-loss drug" is becoming an increasingly inadequate description of what these medications are and do.
What's Been Approved Beyond Diabetes and Weight Loss
The list of expansions is concrete, not speculative.
**Cardiovascular risk.** In 2024, semaglutide became the first weight-management medication approved by the FDA to reduce the risk of major adverse cardiovascular events — heart attack, stroke, cardiovascular death — in adults with obesity or overweight who have established cardiovascular disease, even without type 2 diabetes. This was a notable shift: the drug was approved to prevent cardiovascular events, not just to manage weight or glucose.
**Obstructive sleep apnea.** In December 2024, tirzepatide (under the brand name Zepbound) was approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity. The approval was based on trials in which patients taking the drug had, on average, dramatically larger reductions in sleep apnea events per hour than patients on placebo.
**Chronic kidney disease.** In January 2025, semaglutide (Ozempic) was approved to treat chronic kidney disease in patients with type 2 diabetes. This followed a large trial — stopped early due to strong findings — showing semaglutide significantly reduced the risk of kidney complications. Notably, researchers observed that some of the kidney benefit appeared partly independent of weight change.
**Metabolic liver disease.** In August 2025, semaglutide received accelerated FDA approval to treat metabolic dysfunction-associated steatohepatitis (MASH) — a serious form of fatty liver disease — in adults with moderate to advanced liver scarring. The approval followed a trial published in the New England Journal of Medicine showing significant improvement in liver outcomes.
That is four substantial new indication areas, across four different organ systems, in roughly two years — a pattern documented across recent peer-reviewed reviews of the expanding indications for GLP-1 receptor agonists [3].
Why One Drug Class Affects So Many Systems
The obvious question is how a single class of drugs ends up helping the heart, kidneys, liver, and airways. There appear to be two overlapping answers.
The first is weight loss itself. Obesity is a contributing factor in all of these conditions — it worsens sleep apnea, strains the kidneys, drives fatty liver disease, and increases cardiovascular risk. A drug that produces substantial, sustained weight loss would be expected to improve all of them to some degree, simply by reducing that shared underlying burden. A large real-world analysis presented in 2026 reinforced this: patients who lost the most weight on GLP-1-based medications had substantially lower risks of sleep apnea, chronic kidney disease, osteoarthritis, and heart failure, while those who gained weight fared worse.
The second answer is more interesting and less settled. A 2025 review in the journal Cell Metabolism [1] and a 2026 review in Nature Medicine [2] both describe evidence that GLP-1 medicines have effects that appear partly independent of weight loss — acting through anti-inflammatory and metabolic pathways directly. The kidney disease findings are the clearest example: some of the protective effect showed up in ways not fully explained by weight change [1]. GLP-1 receptors exist in many tissues throughout the body, and the drugs may be doing something more direct than "cause weight loss, which then helps everything" [2].
Both mechanisms are probably operating. Untangling exactly how much of each benefit comes from weight loss versus direct drug effects is an active area of research.
The Open Questions and Cautions
The expanding evidence is real, but several genuine uncertainties remain, and responsible coverage has to name them.
**Long-term safety is still being characterized.** These drugs are being used by enormous numbers of people, but the longest, largest safety datasets are still accumulating [2]. Documented side effects include significant gastrointestinal issues, and researchers continue to investigate questions around muscle loss, and effects in specific contexts [2]. The safety profile is favorable so far for the studied uses, but "so far" is the operative phrase.
**Most trials were done in people with obesity or diabetes.** Much of the evidence base involves patients who have obesity, type 2 diabetes, or both. Whether the same benefits and the same safety profile extend to other populations is not always established.
**Stopping the drug often reverses the benefit.** For weight and metabolic effects, discontinuing the medication frequently leads to regression. The real-world analysis noted that a large fraction of patients discontinue within a year. These are, for many indications, long-term medications, and that has cost, access, and adherence implications.
**Access and cost are substantial barriers.** These drugs are expensive, and insurance coverage for the non-diabetes, non-obesity indications is uneven. An approval does not automatically translate to access.
**Many uses are still investigational.** Beyond the approved indications, GLP-1 medicines are being studied for neurodegenerative disease, substance use disorders, and other conditions. These are early-stage explorations, not established uses, and they should be understood as research questions rather than current treatment options.
How to Think About It
The accurate framing of GLP-1 medicines in 2026 is that they are turning out to be a genuinely consequential class of metabolic drugs whose effects extend across multiple organ systems — more consequential, in scope, than the "weight-loss drug" label suggests. The cardiovascular, kidney, sleep apnea, and liver approvals are based on real trial data, not marketing.
At the same time, this is not a miracle-drug story, and the more enthusiastic coverage sometimes tips in that direction. These are powerful medications with real side effects, real costs, real access barriers, and a safety record that is still being written. They are also not a substitute for the foundational determinants of metabolic health, and for many indications they appear to work only as long as they are taken.
For anyone actually considering one of these medications — for diabetes, weight, or any of the newer indications — the decision genuinely requires individualized medical guidance. The benefits, risks, and trade-offs depend heavily on a person's specific health profile, other conditions, and circumstances. This is precisely the kind of decision that should be made with a qualified healthcare provider who can weigh the full picture, rather than based on a news article or the experiences of others.
Further Reading
The expanding benefits of GLP-1 medicines (Cell Metabolism, 2025) — peer-reviewed review covering cardiovascular, kidney, liver, arthritis, and sleep apnea benefits and the weight-loss-independent mechanisms
ncbi.nlm.nih.gov
The expanding landscape of GLP-1 medicines (Nature Medicine, 2026) — peer-reviewed review of expansion beyond diabetes and obesity, open questions, and long-term safety uncertainties
nature.com
Beyond Diabetes: A Review of Emerging Indications for Glucagon-Like Peptide-1 Receptor Agonists — peer-reviewed review covering heart failure, CKD, MASLD, and the supporting clinical trial data
ncbi.nlm.nih.gov
📢 Advertisement — In-Article Ad